Clinical Trials
60 trialsA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Akeso
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
Xuanwu Hospital, Beijing
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Shanghai Allink Biotherapeutics Co., Ltd.
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
AmiNA
Janssen Research & Development, LLC
MIGRANT
Fundación GECP
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
ImmunityBio, Inc.
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Tang-Du Hospital
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
REVIVE
AstraZeneca
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Massachusetts General Hospital
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HYPERBOLIC
Università Vita-Salute San Raffaele
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
KYLIN-3
Avistone Biotechnology Co., Ltd.
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage â…¡-â…¢B EGFR Sensitive Mutanted NSCLC
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
TYK Medicines, Inc
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Peri-E
Shanghai Chest Hospital
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Example
Hunan Province Tumor Hospital
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
BeBetter Med Inc
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Tang-Du Hospital
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Tel Aviv Medical Center
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd